Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging

Clinical Cancer Research

Volumn 19, Issue 14, 2013, Pages 3914-3924

  Nguyen, Quang Dé ^a   Lavdas, Ioannis ^a   Gubbins, James ^a   Smith, Graham ^b   Fortt, Robin ^a   Carroll, Laurence S ^a   Graham, Martin A ^c   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c TetraLogic Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIRINAPANT; CASPASE 3; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; ICMT 11 F 18; PERFOSFAMIDE; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER TISSUE; CELL STRAIN 38C13; CELL STRAIN HCT116; CELL STRAIN MDA MB 231; CELL VIABILITY; COLON CARCINOMA; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; AZIDES; BREAST NEOPLASMS; CASPASE 3; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; DIPEPTIDES; ENZYME ACTIVATION; FEMALE; HCT116 CELLS; HUMANS; INDOLES; LYMPHOMA, B-CELL; MICE; MICE, INBRED C3H; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881153385     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3814     Document Type: Article

References (31)

1. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1:111-21.
2. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7.
3. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12.
4. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012;149:780-94.
5. Dean E, Greystoke A, Ranson M, Dive C. Biomarkers of cell death applicable to early clinical trials. Exp Cell Res 2012;318: 1252-9.
6. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012;19:107-20.
7. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009;16:3-11.
8. Chen HH, Yuan H, Josephson L, Sosnovik DE. Theranostic Imaging of the kinases and proteases that modulate cell death and survival. Theranostics 2012;2:148-55.
9. Nguyen QD, Challapalli A, Smith G, Fortt R, Aboagye EO. Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11. Eur J Cancer 2012;48:432-40.
10. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A 2009;106:16375-80.
11. Smith G, Glaser M, Perumal M, Nguyen QD, Shan B, Arstad E, et al. Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem 2008;51:8057-67.
12. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
13. Fortt R, Smith G, Awais RO, Luthra SK, Aboagye EO. Automated GMP synthesis of [(18)F]ICMT-11 for in vivo imaging of Caspase-3 activity. Nucl Med Biol 2012;39:1000-5.
14. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009;6:638-47.
15. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6.
16. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101: 2043-8.
17. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
18. Asselin MC, O'Connor JP, Boellaard R, Thacker NA, Jackson A. Quantifying heterogeneity in human tumours using MRI and PET. Eur J Cancer 2012;48:447-55.
19. Galban S, Brisset JC, Rehemtulla A, Chenevert TL, Ross BD, Galban CJ. Diffusion-weighted MRI for assessment of early cancer treatment response. Curr Pharm Biotechnol 2010;11:701-8.
20. Sinkus R, Van Beers BE, Vilgrain V, DeSouza N, Waterton JC. Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. Eur J Cancer 2012;48:425-31.
21. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467:543-9.
22. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10:514-23.
23. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012;11:109-24.
24. Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, et al. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 2008;19:990-5.
25. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-32.
26. Micha D, Cummings J, Shoemaker A, Elmore S, Foster K, Greaves M, et al. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin Cancer Res 2008;14:7304-10.
27. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011;29:909-16.
28. Chen DL, Zhou D, Chu W, Herrbrich P, Engle JT, Griffin E, et al. Radiolabeled isatin binding to caspase-3 activation induced by anti- Fas antibody. Nucl Med Biol 2012;39:137-44.
29. Zhou D, Chu W, Chen DL, Wang Q, Reichert DE, Rothfuss J, et al. [18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98. Org Biomol Chem 2009;7:1337-48.
30. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003;89:1889-95.
31. Brepoels L, De Saint-Hubert M, Stroobants S, Verhoef G, Balzarini J, Mortelmans L, et al. Dose-response relationship in cyclophosphamide- treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging 2010;37: 1688-95.